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Abstract 
Objective: The objective of this systematic review is to determine whether or not topical glyceryl 
trinitrate is an effective treatment for reducing visibility of anal fissures in patients without heart 
disease compared to placebo. 
Study Design: Evidence based review of three randomized controlled trials published in 1999, 
2001, and 2007. 
Data Source: Three randomized controlled trials each evaluating the effectiveness of topical 
glyceryl trinitrate in the treatment of anal fissure, published in the English language, and 
containing exclusion criteria disqualifying participants with a history of heart disease.  
Outcome(s) Measured: Healing was measured via visibility of fissure through examination and 
structured patient interview.  The outcomes were measured by medical professionals, blinded 
consultants, or medical investigative interviewers. 
Results: Average healing rate is 71% for the GTN group and 43% for placebo/lignocaine group. 
Conclusions: Based on the combined evidence this systematic review finds that topical glyceryl 
trinitrate is an effective treatment for reducing visibility of anal fissures in patients without heart 
disease compared to placebo.   
Key Works: anal fissure, glyceryl trinitrate, heart disease 
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Introduction 
Anal fissure is a somatic condition consistently seen in many patient populations.1  An 
anal fissure is a linear tear or ulceration in the anal mucosa often extending from below the 
dentate line to the exterior of the anus.1,2 The tear or ulcer is known to cause extreme pain during 
defecation due to its location below the dentate line.1  The condition is often prolonged due to 
decreased blood flow from the associated spasm of the internal anal sphincter.1  The smooth 
muscle spasm associated with the anal fissure is in theory caused by the lack of nitric oxide 
synthesis, a known inhibitory neurotransmitter.2  The spasm of the internal sphincter additionally 
causes an increase in the maximum resting anal pressure (MRP); as a result, the increased MRP 
causes increased pain and discomfort upon defecation.3  The rise in MRP will also influence 
healing time due to its impact on localized ischemia and unremitting opening of the fissure 
during stooling.4  Ninety percent of anal fissures occur at the posterior commissure, leaving the 
remaining 10% to present at the anterior commissure.4,5  Anal fissures are deemed chronic if they 
present for over six weeks.5  Most anal fissures are visible on physical exam with minor patient 
straining; however, if physical exam fails to uncover the lesion in the setting of elevated clinical 
suspicion, then anoscopy may be required for visualization and diagnosis of fissures.5   
Patients often described the sharp pain associated with anal fissures as the feeling of 
defecating broken glass then enduring burning pain at their anus for hours after.2  While anal 
fissures invoke a certain embarrassing context in layman conversation, the condition has taken its 
place as one of the most common gastrointestinal complaints, and therefore, requires significant 
effort in both research and treatment.1,2  During the lifetime of a patient there is a 7.8-11% 
chance they will develop an anal fissure.1,2  Although males still have a high occurrence rate, 
females have the most cases with 58% of the predicted population based on cohort presentation.1  
From superimposing the cohort results to the 2010 US census population it is predicted that 
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342,000 new diagnoses of anal fissure present in exam rooms across the United States each 
year.1   
The etiology of anal fissures is unclear; however, the condition is largely attributed to 
direct trauma on the anus.1  In the past it has been believed that it is formed by hard stools or 
bouts of diarrhea; on the other hand, a recent study showed that only 25% of newly diagnosed 
anal fissures are preceded by constipation.1  According to cohort data 15% of postpartum 
mothers have anal fissures.1  Crohn’s disease, ulcerative colitis, HIV infection, neoplasia, 
syphilis, and tuberculosis have shown to be prevalent in new diagnoses of rare lateral positioned 
anal fissures.1 
The majority of anal fissures can heal rapidly without medical professional involvement; 
however, the high prevalence of anal fissures in population creates a significant amount patients 
requiring intervention.1  Topical glyceryl trinitrate (GTN) is the non-operative treatment of 
choice.2  GTN is effective both in clinical trials and in pathological theory.2-4  The replacement 
of the inhibitory neurotransmitter, nitric oxide, would in theory restore control of spasm to the 
internal sphincter smooth muscle.2  Many studies have exclaimed the effectiveness and usage of 
GTN on anal fissures in the standard population.1-5  However, with the equal efficacy and 
development of other non-operative treatments, it is crucial to evaluate and the true efficacy of 
GTN based upon ideal patient conditions.5  Systemic absorption of glyceryl trinitrate would 
induce symptoms that can replicate or exacerbate various heart diseases, such as, headache and 
theoretically hypotension.5,6  The headaches are reported in as many as 40% of the patients in 
cohort and have proven to be a reason for patient imposed treatment discontinuation.6  With the 
currently equal efficacy and different side effect profile of other non-surgical treatments, it is 
important to study the effectiveness of GTN in those patients that have less risk of experiencing 
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the side effects, patients without heart disease.5  Reviewing random controlled trials with the 
criteria for cohort selection to exclude participants with heart disease would give an accurate 
assessment of the effectiveness of GTN and possibly propel it to be the undisputed first line 
treatment for years to come.   
There are many treatment options for anal fissure other than GTN.  Conservative 
treatments target sphincter opening and stool softening include hydration, increased fiber intake, 
and stool softeners.2  Calcium channel blockers, botulinum toxin, clove oil, and sildenafil are 
non-operative treatments available.2  Surgical intervention is most commonly administered to 
recurrent or complicated cases; the gold standard surgical treatment is lateral internal anal 
sphincterotomy.2  Surgical intervention has the highest healing rate, but comes with the risk of 
permanent stool incontinence.2 
The cost of treating anal fissures differs depending on the modality and healthcare 
system.  The 2005 United States healthcare system cost of a prescription filling of topical 
glyceryl trinitrate treatment is approximately $10, while outpatient surgical intervention for anal 
fissure is approximately $1119.7  The British model of medicine estimates the cost of treatment 
from check-in to resolution for glyceryl trinitrate is 615.92 pounds ($930.75) and surgical 
intervention is 840.62 pounds ($1270.30).8  The current cost of GTN in the United States is 
$566.9 
Objective 
The objective of this selective evidence based medicine review is to determine whether or 
not topical glyceryl trinitrate is an effective treatment for visible resolution of anal fissures in 
patients without heart disease compared to placebo. 
Methods 
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 This systematic review looked into 3 randomized controlled trials.  The studies each 
included participants with active anal fissures and various ages.  The studies attempted to 
determine the efficacy of GTN when treating anal fissure.  Each study compared GTN to placebo 
or a topical ointment only treating the perception of pain.  The primary outcome measured was 
the visibility of the fissure to determine the level of healing; however, each study also evaluated 
the current level of pain and/or presence of pain upon defecation.   Ahmad et al used 2 
interventions separately on 2 participant groups consisting of: 0.2% GTN ointment BID x 8 
weeks and 5% lignocaine ointment BID x 8 weeks.  To measure outcomes Ahmad et al 
implemented a visual analog scale (VAS) for pain plus a clinical exam with digital rectal exam 
(DRE) and anoscopy; a blinded clinical consultant was used to assess the clinical signs of 
healing.  Kenny et al used 2 interventions separately on 2 participant groups including: 0.2% 
GTN ointment BID x 6 weeks and Placebo paste BID x 6 weeks.  To measure outcomes Kenny 
et al implemented the use of Smiley analogue pain scores and investigator completed clinical 
assessments of symptoms and signs of anal fissure in an outpatient clinic.  Carapeti et al used 3 
interventions separately on 3 participant groups including: 0.2% GTN ointment TID x 8 weeks, 
0.2% GTN ointment weekly titrated 0.1% until 0.6% TID x 8 weeks, and placebo TID x 8 
weeks.  To measure outcomes Carapeti et al implemented clinical examination of the fissure, 
anal manometry, laser Doppler flowmetry, and linear analogue pain charts.  The participants 
involved in the studies had to meet specific criteria including: presence of anal fissure, the ability 
to tolerate and administer treatment, and the ability to give consent via self or guardian.  Further 
demographic and study characteristics can be found in TABLE 1.    
This systematic review evaluated each article and compared the treatment times as 
outlined by visibility of fissure to determine the efficacy of GTN treatment on patients with anal 
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fissures and without heart disease. Each article was published in academic journals and released 
in the English language.  The author researched the articles via PubMed through the PCOM 
Library website using the key words: glyceryl trinitrate, anal fissure, and heart disease.  Articles 
were selected based upon their relevance to the desired topic, date of publication, language, and 
exclusion criteria.  Statistics reported or used include: p-values, absolute benefit increase (ABI), 
numbers needed to treat (NNT), and numbers needed to harm (NNH).  
TABLE 1 – Demographics & Characteristics of included studies 
 
Study Type # 
Pts 
Age 
in 
Years 
Inclusion Criteria Exclusion Criteria W
/
D 
Interventions 
Ahmad 
J, 2007 
RCT 50 9-59  Patients with an anal 
fissure that consent to 
the study and can 
apply a pea sized 
amount of ointment 
to the area as 
directed.  
Patients with 
perianal fistula, 
perianal abscess, 
inflammatory bowel 
disease, ischemic 
heart disease, 
migraine, and 
pregnancy.  
5 0.2% GTN 
BID x 8 weeks 
 
5% lignocaine 
BID x 8 weeks 
Kenny 
SE, 2001 
RCT 40 0.7-
15.9  
Positive diagnosis of 
anal fissure with 
visibility and pain 
with defecation. 
History of recurrent 
fissure, congenital 
heart disease, or 
severe headaches. 
9 0.2% GTN 
BID x 6 weeks 
 
Placebo paste 
BID x 6 weeks 
Carapeti 
EA, 
1999 
RCT 70 21-72 Patients with anal 
fissure for three 
months duration or 
longer, with clinical 
features of chronicity 
such as fibrosis of the 
base of the ulcer or 
associated sentinel 
pile. 
Pregnant women, 
patients already on 
nitrate treatment for 
ischemic heart 
disease, patients 
with fissures 
attributed to an 
underlying 
identifiable 
pathology such as 
Crohn’s disease or 
HIV, and patients 
with a history of 
migraine. 
2 0.2% GTN TID 
x 8 weeks 
 
0.2% GTN 
weekly titrated 
up to 0.6% TID 
x 8 weeks 
 
Placebo x 8 
weeks 
 
Outcomes Measured 
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GTN, lignocaine, and placebo supplemented healing was measured via visibility of 
fissure and pain through physical examination and structured patient interview.  The outcomes 
were measured by medical professionals, blinded consultants, or investigative clinicians.  Tools 
used to measure outcomes included clinical expertise, anoscopy, anal manometry, laser Doppler 
flowmetry, linear analogue pain charts, Smiley analogue pain scores, and DREs.  
Results 
 Ahmad et al used 50 participants and randomly divided them into 2 groups.  The first 
group of 25 participants received GTN and the second lignocaine.  See TABLE 1 for dosage and 
criteria.  There were 18 females and 32 males divided at random.  The average age was 31.28 
with a low of 9 and a high of 58 years old.  There were no participant drop outs or 
disqualifications from the study.  Healing was determined based on defecation pain score, 
clinical exam, and disappearance of fissure.  After 8 weeks of treatment the GTN group 
experienced fissure healing in 80% of the patients compared to the 32% in the lignocaine group 
with a p-value of less than 0.002.  Headaches occurred in 68% of the GTN group compared to 
32% in the lignocaine group with a p-value of 0.01.  Pruritis ani and postural hypotension 
occurred in a minority but was deem not statistically significant.   The NNT for the GTN is 3 to 
illicit significant clinical benefit.   The NNH for GTN headaches is 2 and postural hypotension is 
12.  See TABLE 2 for healing and side effects data.   
TABLE 2 – Healing and side effects data for Ahmad et al 
 GTN Group 
(n=25) 
Lignocaine Group 
(n=25) 
p-value NNT/NNH 
Healing at 8 weeks 20 (80%) 8 (32%) P < 0.002 NNT = 3 
Headache 17 (68%) 7 (28%) P = 0.01 NNH = 2 
Pruritis ani 2 (8%) 4 (16%) Not 
significant 
* 
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Postural 
hypotension 
1 (4%) 0 Not 
significant  
NNH = 12 
*lignocaine group cannot be used as control due to its potential for causing pruritis ani 
 Carapeti et al used 70 patients ranging from 21-72 years old with a mean age of 35.  The 
participants were randomly divided into 3 groups.  Two groups of 24 participants underwent 
GTN treatment at various titrations (see TABLE 1) and the placebo group consisted of 22.  One 
person in each of the GTN groups dropped out due to one not having a fissure and the other 
becoming uncontactable.  One person in the placebo group did not finish the study due to 
needing a lateral sphincterotomy and was considered to be treatment failure.  Healing was 
determined based on clinical examination of fissure, anal manometry, and laser Dopplar 
flowmetry.  After treatment and a 2 week waiting period 32% of the placebo group, 65% of the 
0.2% GTN, and 70% of the titrated GTN were found to have healed with a p-value of 0.008. The 
p-value was calculated based on placebo versus combined GTN healing rate.  Headaches were 
experienced in 72% of the combined GTN groups and 27% of the placebo with a p-value of 
<0.001).  The NNT for GTN is 3 to illicit significant clinical benefit.  The NNH in the form of 
headaches by GTN 2.  See TABLE 3 for healing and side effects data.   
TABLE 3 – Healing and side effects data for Carapeti et al 
 GTN 
(n=23) 
GTN titrated 
(n=23) 
Placebo 
(n=22) 
p-value NNT/NNH 
Healing at 10 
weeks 
15 (65%) 16 (70%) 7 (32%) P = 
0.008 
NNT = 3 
Headache 33 (72%) combined GTN groups
  
6 (27%) P < 
0.001 
NNH = 2 
 
 Kenny et al used 40 participants ranging from 0.7 to 15.9 years old with a mean age of 
3.83.  The participants were randomly divided into 2 groups.  The GTN group received 20 
participants and the placebo received 20.  The 2 groups received treatment base on their group 
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(see TABLE 1) and a daily dose of oral senna and lactulose.  For various reasons outside of 
know GTN side effects, the GTN group had 7 participants drop out compared to the placebo 
group’s 2 (see TABLE 4).  Two of the GTN group’s participants were present for the 6-week 
evaluation and included in this systematic review as participants. Healing was determined via an 
outpatient physical exam by medical investigators blind to treatment group allocation. At week 6 
visible fissure was resolved in 54.4% of the GTN group compared to 75% in the placebo group 
with no p-value given (see TABLE 5).  The ABI is -26.5% for treatment with GTN.  Due to the 
significant difference in fissure visibility in the placebo and GTN groups at 6 weeks, the NNH 
for GTN by way of prolonging visibility of fissure is 4 (see TABLE 5).  None of the participants 
reported headache. 
TABLE 4 – Participant withdrawal profile10 
Group Age (year) Sex 
When withdrew 
(week) 
Pain score on 
withdrawal Reason 
GTN 2.4 F 7 0 Lost contact 
GTN 2.7 F 11 8 Persistent high pain scores; no 
fissure when examined under 
anesthetic 
GTN 1.3 F 5 8 Persistent high pain scores; 
coryzal symptoms thought by 
parents to be due to GTN 
GTN 0.7 M 1 10 No reason given 
GTN 1.2 F 4 8 Perineal rash; examination 
under anesthetic at week 4: 
fissure healed, pain free at 8 
weeks and oV laxatives 
GTN 1.2 M 1 8 Gastrointestinal upset (colicky 
pains and vomiting) 
GTN 3.6 F 14 2 Parental dissatisfaction with 
improvement; underwent 
fissurectomy 
Placebo 1.8 F 8 9 Persistent high pain scores; 
underwent fissurectomy 
Placebo 2.6 M 8 7 Persistent high pain scores; 
underwent fissurectomy 
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TABLE 5 – Healing data for Kenny et al 
 GTN (n=15) Placebo (n=16) ABI of GTN NNH for GTN 
Healing at 6 weeks 8 (54.4%) 12 (75%) -21.66% 4 
 
 Combining the data from all studies involved in this review produces a healing rate of 
71% for the GTN group and 43% for placebo/lignocaine group (see TABLE 6).   
TABLE 6 – Combined Healing data 
 GTN (n=86) Placebo/lignocaine (n=63) 
Healing at 6-8 weeks 61 (71%) 27 (43%) 
 
Discussion 
This systematic review is comprised of studies that both support and reject the efficacy of 
using GTN for treating anal fissures in patients without heart disease.  There are a few important 
points that need to be discussed before a conclusion can be constructed.   
GTN is labeled for use in angina/coronary artery disease and anal fissure.9  The off label 
uses include esophageal spastic disorders, gastroesophageal variceal hemorrhage, 
sympathomimetic vasopressor extravasation injury, uterine relaxation, and short-term 
management of pulmonary hypertension.9  Contraindications to GTN include hypersensitivity to 
organic nitrates, concurrent use of phosphodiesterase-5 inhibitors or riociguat, increased 
intracranial pressure, and severe anemia.9  Systemic absorption is known to have adverse drug 
reactions in some cases including but not limited to: bradycardia, flushing, hypotension, 
orthostatic hypotension, peripheral edema, syncope, tachycardia, headache, dizziness, 
lightheadedness, nausea, vomiting, and diaphoresis.9  The adverse drug reactions are the primary 
reason this study chose to reject random controlled trials that failed to add heart disease to their 
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exclusion criteria.  The adverse drug reactions have the potential to simulate symptoms of heart 
disease.  Excluding people with heart disease reduced the risk of GTN group dropout and 
maladaptive administration; therefore, the exclusion criteria requirement gave a better estimate 
on how GTN works on anal fissures without the confounding of variable from comorbid 
conditions.  
The age gap between the studies may have had an effect on the results.  Ahmad et al and 
Carapeti et al had participant age averages of 31.28 and 35 years old.  Kenny et al had an average 
participant age of 3.83 years old.  While the pathology and treatment remains the same, the 
younger patient population was less successful with GTN treatment.  Kenny et al self-identified 
as an outlier compared to other similar studies in the discussion section of their study and 
attempted to explain why their results were different.  A lower age group has been hypothesized 
to change voiding habits in response to pain, for example less frequent voiding, which can 
increase the maximum resting anal pressure and reduce the efficacy of treatment.9   Kenny et al 
also had the highest withdrawal rate associated with the GTN group.  While the age difference is 
cause for further investigation regarding its impact on GTN efficacy, age was not a specified 
exclusion parameter in this systematic review and likely introduced confounding variables.  
 Ahmad et al and Carapeti et al displayed adverse events associated with GTN.  Both 
studies had headaches in a significant number of their GTN patients.  With a NNH of 2, the 
headache prevalence is an important side effect to communicate to patients.  One patient reported 
postural hypotension in the GTN group of Ahmad et al, producing a NNH of 12.  Both of the 
studies did not lose any participants to side effect related symptoms in the GTN group; therefore, 
when educating patients on GTN side effects it is important to highlight the likely mild severity.  
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With all of the differences aside, two of the three articles, Ahmad et al and Carapeti et al, 
conclude GTN is an effective treatment and found success rates much higher than expected.  
Ahmad et al and Carapeti et al both produced data that establishes a NNT of 3 for GTN from 
their EER values of 80% and 72% respectively.  Kenny et al found that GTN was an ineffective 
treatment.  Furthermore, if prolonged healing were to be considered an adverse drug reaction, 
then the data from Kenny et al could conclude that GTN in fact has a NNH of 4.  While the 
studies greatly differed in many areas, they fit the parameters of this systematic review and 
thereby must all be given equal strength in the evaluation and fulfilment of this systematic 
review’s objective.  Even though the majority supported the use of GTN, Kenny et al produced 
results that without question rejects the use of GTN.  
Conclusion 
 Based on the combined evidence this systematic review finds that topical glyceryl 
trinitrate is an effective treatment for reducing visibility of anal fissures in patients without heart 
disease compared to placebo.  A secondary finding is the adverse drug reactions of GTN are not 
significant enough to cause patients without heart disease to discontinue treatment.  Age and 
confounding variables may have played a role in reducing the overall efficacy of GTN in this 
review; however, the evidence supporting GTN treatment is convincing enough to overcome one 
random controlled trial reporting the contrary.  The inclusion of a study with a low average 
participant age, Kenny et al, was a flaw in the methods of this systematic review.  To reduce risk 
of confounding variables and better evaluate the efficacy of GTN in ideal patients, future reviews 
should target studies that require patients developed enough to properly administer their own 
treatment and provide supportive care for their fissure.   
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